The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia
Open Access
- 2 September 2013
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 53 (5) , 597-604
Abstract
Background. Recently, the Quantitative Analysis of Normal Tissue Effect in the Clinic (QUANTEC) Group defined dose-volume constraints for the parotid glands to avoid severe xerostomia. The aim of this study was to determine if application of these QUANTEC criteria also protected against moderate-to-severe patient-rated xerostomia. Material and methods. The study population consisted of 307 head and neck cancer patients treated with primary (chemo)radiotherapy, either with 3D-CRT (56%) or with IMRT (44%). All patients participated in a standard follow-up program in which radiation-induced toxicity and quality of life were prospectively assessed. Patients who met the QUANTEC criteria were classified as low risk and otherwise as high risk. Results. In total, 41% of the patients (treated with 3D-CRT and IMRT) were classified as low risk patients. In the group treated with 3D-CRT and IMRT, it was possible to meet the QUANTEC criteria in 47% and 32% of the patients, respectively. Sparing the parotid glands with IMRT was considerably more difficult in patients with lymph node metastases and in patients with nasopharyngeal and oropharyngeal tumours. Low risk patients reported significantly less moderate-to-severe xerostomia than high risk patients. However, the predicted risk of elderly patients and patients with pre-existing minor patient-rated xerostomia at baseline was > 20%, even when the QUANTEC criteria were met. Conclusions. Significantly lower rates of radiation-induced patient-rated xerostomia were found among low risk patients treated according to the QUANTEC criteria, but these criteria do not completely protect against xerostomia. Particularly in elderly patients and patients already suffering from minor xerostomia at baseline, the QUANTEC criteria do not sufficiently protect against persistent, moderate-to-severe patient-rated xerostomia.Keywords
This publication has 15 references indexed in Scilit:
- Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of dosimetric and clinical factorsRadiotherapy and Oncology, 2012
- Treatment Planning Constraints to Avoid Xerostomia in Head-and-Neck Radiotherapy: An Independent Test of QUANTEC Criteria Using a Prospectively Collected DatasetInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialThe Lancet Oncology, 2011
- Radiotherapy Dose–Volume Effects on Salivary Gland FunctionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific IssuesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Delineation guidelines for organs at risk involved in radiation-induced salivary dysfunction and xerostomiaRadiotherapy and Oncology, 2009
- Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma PatientsJournal of Clinical Oncology, 2007
- Impact of Radiation-Induced Xerostomia on Quality of Life After Primary Radiotherapy Among Patients With Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patientsEuropean Journal of Cancer, 2000